Timothy A. Chan
Oncology · 2012–2022
A researcher in the Science corpus: 25 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 402 citations into it
- Immunology — 331 citations into it
Whom Timothy A. Chan trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from Timothy A. Chan's perspective
Ordered by how strongly the researchers Timothy A. Chan trusts endorse each paper. Same corpus, a different order for every researcher.
- PD-1 blockade in tumors with mismatch repair deficiency. (Journal of Clinical Oncology)
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma (New England Journal of Medicine)
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
- Pembrolizumab for the treatment of non-small-cell lung cancer. (New England Journal of Medicine)
- PD-1 blockade induces responses by inhibiting adaptive immune resistance (Nature)
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
- Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells (Nature Medicine)
- Neoantigens in cancer immunotherapy (Science)
- Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted… (Journal of Clinical Oncology)
- Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma (New England Journal of Medicine)
Their papers
- IDH mutation impairs histone demethylation and results in a block to cell differentiation (2012) — 1,923 citations
- Comprehensive Molecular Characterization of Human Colon and Rectal Cancer (2012) — 7,754 citations
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype (2012) — 1,888 citations
- Genetic basis for clinical response to CTLA-4 blockade in melanoma. (2014) — 3,876 citations
- An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells (2013) — 1,105 citations
- Abstract B32: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses (2016) — 684 citations
- Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures (2016) — 623 citations
- Identification of unique neoantigen qualities in long term pancreatic cancer survivors. (2017) — 1,016 citations
- Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape (2022)
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (2020) — 916 citations
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types (2019) — 3,368 citations
- The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy (2019) — 1,999 citations
- Immunogenic neoantigens derived from gene fusions stimulate T cell responses (2019)
- CD8+ T cells regulate tumor ferroptosis during cancer immunotherapy (2019) — 2,406 citations
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic (2018) — 2,243 citations
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2017) — 995 citations
- Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab (2017) — 1,995 citations
- A neoantigen fitness model predicts tumor response to checkpoint blockade immunotherapy (2017) — 598 citations
- The head and neck cancer immune landscape and its immunotherapeutic implications. (2016) — 675 citations
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade (2016) — 2,796 citations